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Summary
Objective: To investigate the modulation of expression of proteinase-activated receptor-2 (PAR-2) in articular chondrocytes by inﬂammatory
cytokines.
Design: Articular synovium and cartilage tissues were collected from eight patients with osteoarthritis (OA), and three patients without arthrop-
athy (‘‘normal’’). Chondrocytes were stimulated with interleukin (IL)-1b, tumor necrosis factor (TNF)-a or transforming growth factor (TGF)-b1.
The expression of PAR-2 was detected using reverse transcriptase-polymerase chain reaction (PCR), Western blotting and immunoﬂuores-
cence. Quantitative PCR was performed to assess the expression levels of PAR-2 messenger RNA (mRNA).
Results: The expression of PAR-2 mRNA was demonstrated in both OA and normal chondrocytes as well as in synovial ﬁbroblasts. However,
the level of PAR-2 in OA chondrocytes was much higher than in normal chondrocytes. Long-term culture revealed that PAR-2 mRNA expres-
sion was maintained up to three passages in OA but not in normal chondrocytes. IL-1b and TNF-a both upregulated PAR-2 expression in
normal and OA chondrocytes. In contrast, TGF-b1 signiﬁcantly decreased expression of PAR-2 in OA chondrocytes but increased PAR-2
in normal chondrocytes.
Conclusions: Overexpression of PAR-2 in OA chondrocytes is upregulated by proinﬂammatory cytokines IL-1b and TNF-a, and down-
regulated by regulatory cytokine TGF-b1. PAR-2 may be involved in the pathogenesis of OA.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Proteinase-activated receptors (PARs), a family consisting
of four members from PAR-1 to -4, belong to the G pro-
tein-coupled seven transmembrane domain receptor super-
family and have a unique mechanism for activation of the
receptors by serine proteinases such as thrombin, trypsin,
and mast cell tryptase. The proteinase cleaves the extracel-
lular domain of the receptor, releasing the N-terminal
sequence. A ﬁve or six amino acid tethered peptide ligand
can then bind to the binding site of the receptor1,2. Activated
PARs play important roles in the control of the coagulation
cascade, inﬂammatory response, vascular and airway
contractility, and survival of neural cells3,4.
AmongPARs, PAR-2 is unique in that it is activated by tryp-
sin, tryptase and other trypsin-like proteinases (e.g., mem-
brane-type serine protease-15, human airway trypsin-like
protease, stratum corneum tryptic enzyme6, 22 kDa trypsin-
like serine protease, transmembrane serine protease-37,
coagulation factor VIIa and Xa8, human leucocyte elastase,
cathepsin G, and neutrophil-derived serine protease 39),
but not by thrombin which activates the other three members
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Received 6 September 2005; revision accepted 18 April 2006.1of the PAR family1,8,10e12. PAR-2 is present in a variety of
tissues and cells, including kidney, cardiovascular system,
airway, stomach, intestine, skin, bladder, and brain, where
it is localized to epithelial and endothelial cells, myocytes,
ﬁbroblasts, neurons, and glial cells10, as well as in immune
cells including neutrophils, eosinophils, lymphocytes, mast
cells, and dendritic cells13,14.
The signaling pathway following activation of PAR-2 in-
cludes activation of phospholipase Cb via Gq/11 protein,
which produces inositol triphosphates followed by Ca2þmo-
bilization and diacylglycerol followed by activation of protein
kinase C15. In addition, PAR-2 can activate MEK1/2-ERK1/
2, mediating cell proliferation16.
Osteoarthritis (OA) is a degenerative joint disease in
which degradation of the cartilage structure is observed.
OA is generally considered to be a noninﬂammatory joint
disease; however, recent investigations demonstrated the
signiﬁcant involvement of inﬂammatory processes in OA
pathogenesis17. In this regard, besides synovial ﬁbroblasts,
articular chondrocytes in cartilage are known to secrete an
array of proinﬂammatory cytokines, including interleukin
(IL)-1 and tumor necrosis factor (TNF) a, as well as protein-
ases into the extracellular matrix (ECM) upon stimulation,
for example by urokinase-type plasminogen activator18, ca-
thepsin K19, and granzyme B20. These trypsin-like enzymes
are reported to be potent activators of PAR-2.
In light of this, it is possible that the PAR-2 system is in-
volved in the inﬂammatory response-mediated degradation
of ECM in OA. Nevertheless, thus far little is known about163
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lage. In particular, elucidation of the effect of inﬂammatory
cytokines such as IL-1 on PAR-2 expression in chondro-
cytes will be important in understanding the pathogenesis
of OA. To investigate this issue, we analyzed here the ex-
pression of PAR-2 and its regulation by representative
inﬂammatory cytokines in human articular chondrocytes,
using both primary cultures and cell lines.
Materials and methods
ARTICULAR CARTILAGE AND SYNOVIAL TISSUE
Human articular cartilage and synovial tissue were ob-
tained from eight OA patients (ages 62e87 years, mean
73.2 years, seven women and one man, ﬁve knee joints
and three hip joints) diagnosed according to the American
Rheumatism Association criteria for classiﬁcation21, who un-
derwent arthroplasty, as well as from three healthy people
with femoral fractures at total arthroplasty (ages 63e87
years, mean 74.6 years, two women and one man) as con-
trols. All samples were obtained at the department of ortho-
paedics of St Marianna University Hospital with informed
consent and this study was approved by the institutional
ethics committee.
CELL CULTURE AND STIMULATION
Chondrocytes were prepared as described previously22.
Brieﬂy, cartilage was minced into small pieces, and
digested by rotating overnight at 37(C in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) (Gibco BRL,Grand
Island, NY) containing 1 mg/ml of bacterial collagenase
(Sigma, St Louis, MO). The released chondrocytes were
ﬁltered through a sterile nylon strainer (Becton Dickinson,
Franklin Lakes, NJ) and washed in DMEM three times.
Half of the cells were used for extracting total RNA. The
remainder were seeded onto the surface of ﬂasks coated
with collagen I (Becton Dickinson) at a cell density of
5 105/ﬂask and cultured in DMEM containing 10%
heat-inactivated fetal calf serum (FCS) (Gibco BRL),
100 U/ml penicillin and 100 mg/ml streptomycin (Gibco
BRL) at 37(C in a humidiﬁed atmosphere of 5% CO2.
The medium was replaced every 3 days.
When chondrocytes at passage 1 reached 90% conﬂu-
ence, the plates were washed with phosphate buffered
Saline (PBS) three times, and then fed with FCS-free
DMEM with or without IL-1b (10 ng/ml), TNF-a (10 ng/ml),
or transforming growth factor (TGF)-b (1 ng/ml) and were
harvested at 12, 24 and 48 h after stimulation for time
course analysis. The chondrocytes were also cultured for
24 h in different concentrations of the stimulants.
Synoviocytes were obtained from synovial membrane, as
described by Vallejo et al.23. Brieﬂy, synovial membrane
was digested with 1 mg/ml collagenase type I (Worthington
Biochemical, Freehold, NJ) in DMEM for 4 h at 37(C in 5%
carbon dioxide and cultured in DMEM containing 10% FCS,
100 U/ml penicillin and 100 mg/ml streptomycin. Only ﬁbro-
blast-like synoviocytes (FLS) which were adherent were
used in the study. To compare the difference in expression
of PARs between FLS and chondrocytes, passage 1 cul-
tured FLS were used in this experiment.
Human pulmonary epithelial cells (A549), purchased from
DAINIPPON Pharm. Co, Tokyo, Japan, were cultured in
DMEM containing 10% FCS. Human umbilical vein endo-
thelial cells (HUVEC), also purchased from DAINIPPONPharm. Co, were cultured in MCDB 131 medium (Sigma)
containing 5% FCS and growth factors (10 ng/ml epithelial
growth factor (EGF), 10 ng/ml ﬁbroblast growth factor
(FGF)).
TOTAL RNA EXTRACTION AND COMPLEMENTARY DNA
SYNTHESIS
For evaluating the expression of PARs and themessenger
RNA (mRNA) level of PAR-2 in articular chondrocytes, total
RNA was extracted from ‘‘fresh chondrocytes’’ which were
separated from cartilage tissues but not cultured; and ‘‘pri-
mary chondrocytes’’ which were cultured to conﬂuence but
not passaged. To investigate the regulation of expression
of PAR-2 in chondrocytes, total RNA was extracted from
passage 1 cultured chondrocytes stimulated with or without
the stimulants as indicated. Total RNA from FLS was ex-
tracted from passage 1 cultured cells. Total RNA from
A549 and HUVEC cells was also extracted from cultured
cells as positive controls for PARs10,24. RNA Zol B (Friends-
wood, TX) and chloroformwere used for extracting total RNA
according to the manufacturer’s instructions. The cells were
lysed directly in the culture dish to avoid trypsinization. Com-
plementary DNA (cDNA) was reverse-transcribed from
20 mg total RNA in a 20 ml reaction mixture containing
500 mMeach of deoxynucleotide triphosphates, 0.4 U/ml RN-
ase inhibitor, 0.2 mg/ml of random primers and 2.5 mM of
reverse-transcriptase (Invitrogen, CA). The reaction mixture
was incubated in a DNA thermal cycler at 42(C for 2 h then
stored at 20(C before use.
POLYMERASE CHAIN REACTION
Using the nucleotide sequences of the cDNAs of human
PARs, we prepared four pairs of DNA primers for PARs by
reverse transcriptase-polymerase chain reaction (RT-PCR)
and real-time PCR, a pair of collagen type II DNA (COL2A1)
primers, and a pair of b-actin DNA primers as control
(shown in Table I). PCR was performed with these se-
quence-speciﬁc primer pairs (Table I) and Taq DNA poly-
merase (Takara) in a 25-ml PCR reaction as described25.
Brieﬂy, 2 ml of synthesized cDNA template, 2 ml of 2.5 mM
deoxynucleotide triphosphates (dNTP), 2.5 ml of 10 Taq
buffer, 0.2 ml of Taq polymerase, 2 ml of speciﬁc primers,
and 16.3 ml of water were mixed in a reaction tube. The
PCR was carried out for 35 cycles of 1 min at 95(C,
1 min at 60(C, and 1 min at 72(C. After ampliﬁcation, the
products were visualized by electrophoresis through a 2%
agarose gel, staining with 1 mg/ml ethidium bromide, and il-
lumination with a ultraviolet (UV) lamp. The cDNA sequence
of PAR-2 fragments was further identiﬁed using an ABI
PRIM 3100 Genetic Analyzer (Applied Biosystems Japan
Lid, Hitachi, Japan) (data not shown).
PREPARATION OF STANDARDS AND REAL-TIME PCR
PCR-Blunt-II-TOPO (Invitrogen) was used to prepare
standards of PAR-2 to evaluate the mRNA copies of
PAR-2, COL2A1, and b-actin, according to the manufactur-
er’s instructions. Brieﬂy, the cDNA of PAR-2, COL2A1, and
b-actin was ampliﬁed in a 25-ml PCR reaction and then
puriﬁed with 1.5% low-melt agarose. Puriﬁed cDNA of
PAR-2, COL2A1, and b-actin was then ligated into TOPO
vectors with a 6-ml ﬁnal reaction volume for 5 min at room
temperature. The ligated vectors were transformed into
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Primer specifications for RT-PCR and real-time PCR
Primers Sequence (50e30) Starteend (bp) AT* ((C) Cycles
PAR-1 Sense 50GCC TCT CGT CCT CAAG 705e991 60 35
Antisense 50CGT TTG TGG GTC CGA A (287)
PAR-2 Sense 50CTG CCT ATG TGC TGA T 779e1094 60 35
Antisense 50CGG ACA CTT CGG CAA A (316)
PAR-3 Sense 50ATC AAC CGC TAC CTG G 565e765 60 35
Antisense 50TGA GGA CTC GCA AGT G (201)
PAR-4 Sense 50CTG CAT TAC TCG GAC CC 913e1153 60 35
Antisense 50GGA GCA AAG AGG AGT GG (241)
COL2A1 Sense 50GGAGTCAAGGGTGATCG 3157e3407 60 35
Antisense 50GTGAAGCCACGGTGTC (251)
b-Actin Sense 50ATCCGCAAAGACCTGT 113e346 60 35
Antisense 50GCCGGACTCGTCATAC (234)
*AT, Annealing temperature.One Shot Chemically Competent E. coli, and transformed
E. coli were inoculated into low-salt Luria-Bertani
(LB) plates containing 25 mg/ml of Zeocin and incubated
overnight at 37(C. Clones of E. coli were then picked and
incubated in 2.5 ml of low-salt LB medium containing
25 mg/ml of Zeocin overnight at 30(C. When the ampliﬁed
plasmids were extracted from E. coli, the cDNA inserts of
PAR-2, COL2A1, and b-actin in the vectors were identiﬁed
by digestion with EcoR I restriction enzyme followed by
PCR using target-speciﬁc primers and vector-speciﬁc M13
primers. According to the concentration and molecular
weight of vectors, the target-loaded plasmid was then
diluted to 5, 50, 500, 5000, and 50,000 copies/ml and then
stored at 20(C before use.
Real-time PCR was performed using a LightCycler with
the LightCycler-FastStart DNA Master SYBR Green I kit
(Roche, Germany) according to the manufacturer’s instruc-
tions. Brieﬂy, the cDNA template of each sample was diluted
to 100 ng/ml, and then 2 ml of cDNA sample was added to an
18 ml reaction mix made up of 11.6 ml of sterilized water,
2.4 ml of MgCl2 stock solution, 2 ml of speciﬁc primers, and
2 ml of LightCycler-FastStart DNA Master SYBR Green I.
The preincubation was at 95(C for 15 min. The annealing
temperature was 60(C and the reaction was performed for
35 cycles. To evaluate the mRNA copy number of PAR-2,
COL2A1, and b-actin, a standard curve for each target was
prepared by amplifying the target cDNA from a series of di-
luted constructs [Fig. 2(a)].
WESTERN BLOTTING
Whole cell lysates were obtained without trypsin digestion
from passage 1 FLS and passage 1 chondrocytes without or
with stimulation by IL-1b (10 ng/ml), TNF-a (10 ng/ml), and
TGF-b (1 ng/ml) for 24 h. Twenty micrograms of FLS and
chondrocyte proteins from each well was separated by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis.
The proteins in the gels were transferred onto polyvinylidene
ﬂuoride membranes (Amersham Bioscience, Buckingham-
shire, UK) after electrophoresis. The membranes were
then blocked in PBS containing 5% skimmed milk and
0.05% Tween 20 for 1 h, and then incubated with mouse
anti-human PAR-2 monoclonal antibody (SAM11) (Santa
Cruz Biotechnology, Inc., CA) at 1:200 in PBS containing
0.05% Tween 20 (PBST) at 4(C overnight26. The epitope
mapping of this antibody is within amino acids 37e50 ofPAR-2 of human origin. It can speciﬁcally recognize the
PAR-2molecule from human, mouse and rabbit but not other
molecules. After washing in PBST, the bound antibodies
were reacted with horseradish peroxidase-conjugated
sheep anti-mouse immunoglobulin (Ig)G (Amersham Biosci-
ence) at 1:10,000 for 1 h. Finally, the bound antibodies were
visualized with enhanced chemiluminescence (ECL) detec-
tion reagents and autoradiographic ﬁlm (Amersham Biosci-
ence). The glyceroldehyde-3-phosphate dehydrogenase
(GAPDH) level in the same cell lysate was tested at the
same time. The relative level of PAR-2 was evaluated by
the ratio of band intensity according to the formula PAR-2
band intensity/GAPDH band intensity.
IMMUNOFLUORESCENCE ASSAY (IFA)
Both normal and OA chondrocytes at passage 1 were
seeded in eight-well chamber-slides and cultured for 2 days
to reach 20e50% conﬂuence, and then incubated in the ab-
sence or presence of IL-1b (10 ng/ml in FCS-free medium),
TNF-a (10 ng/ml), and TGF-b (1 ng/ml) for 24 h. The slides
were stained using standard immunoﬂuorescence tech-
niques27 with some modiﬁcations. In brief, the slides were
washed in PBS, then ﬁxed in 2% formaldehyde in PBS. After
washing twice, PBS containing 1.5% (v/v) inactivated goat
serum (pH 7.1) was used to block nonspeciﬁc binding sites.
The slides were then incubated with 1:200 diluted mouse
anti-PAR-2 monoclonal antibody (SAM11) for 1 h at room
temperature in a humidiﬁed chamber. Slides were rinsed
three times in washing buffer (PBSþ 0.05% Tween 20) and
were subsequently incubated with polyclonal goat anti-
mouse IgG conjugated with ﬂuorescein isothiocyanate
(FITC; BD PharMingen, CA) at a dilution recommended by
the manufacturer. After rinsing in distilled water, the slides
were viewed using an epiﬂuorescence microscope.
STATISTICAL ANALYSIS
Results were normalized to the copy numbers of b-actin.
The mean and standard deviation were used to evaluate
the PAR-2 mRNA level. Student’s t test was used for com-
parison of the difference in expression level of PAR-2
between OA and normal chondrocytes, and between chon-
drocytes and FLS. The effects of the stimulation by cytokines
on PAR-2 expression were analyzed as changes relative to
unstimulated baseline, using repeated measure analysis of
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comparisons. These analyses were performed individually
and for the group as a whole. Statistical signiﬁcance was
set at P< 0.05.
Results
PAR-2 IS EXPRESSED AT A HIGHER LEVEL IN OA THAN IN
NORMAL CHONDROCYTES
All four members of the PAR family were detected in
A549 cells, as were three members of the PAR family in
HUVEC cells, as shown in Fig. 1. mRNA of PAR-1 and
PAR-2 was detected in normal FLS (NFLS), while PAR-1,
PAR-2, and PAR-3 were detected in OA FLS (OFLS). How-
ever, only PAR-2 was detected in normal and OA articular
chondrocytes (NC and OC; Fig. 1). These results illustrate
the difference in expression patterns of PAR family mem-
bers between cell types, and the preferential expression
of PAR-2 in human articular chondrocytes.
To further evaluate the levels of PAR-2 mRNA in chon-
drocytes we performed real-time PCR. The PAR-2 mRNA
Fig. 1. Expression of the PAR family in human articular chondro-
cytes. RT-PCR was performed to detect PARs mRNA in the target
cells. This was repeated three times for each sample, and repre-
sentative results are shown. b-Actin and PAR-1 to -4 were ampliﬁed
from the cDNA of target cells. Total RNA was extracted from the fol-
lowing samples: human pulmonary epithelial cells (A549, line 1),
HUVEC (line 2), primary synovial ﬁbroblast-like cells from three nor-
mal synovial tissues (NFLS, line 3; a representative result) and from
eight patients with OA (OFLS, line 4; a representative result), uncul-
tured fresh chondrocytes separated from three normal articular car-
tilage tissues (NCT, line 5; a representative result) and from eight
OA patients (OCT, line 6; a representative result), primary chondro-
cytes from three individual normal cartilage samples (NC-1 to NC-3,
lines 7e9) and from eight individual OA cartilage samples (OC-1
to OC-3, lines 10e12; three representative results). Water was
used in place of cDNA from target cells as a negative control
(water, line 13).level in OA chondrocytes was seven times higher than in
normal ones, suggesting overexpression of PAR-2 in OA
chondrocytes. However, the levels of PAR-2 both in nor-
mal and OA chondrocytes were much lower than in FLS
from patients with or without OA. The differences were
highly statistically signiﬁcant between normal and OA
cells, between normal chondrocytes and NFLS, and be-
tween OA chondrocytes and OFLS (P< 0.001 in each
case) (Fig. 2).
We also conﬁrmed the expression of PAR-2 in human
FLS and articular chondrocytes at the protein level
[Fig. 3(a)]. As shown, PAR-2 expression was observed
both in normal and OA samples, and the expression level
was higher in OA samples (P< 0.05), consistent with the
results of PCR.
EFFECT OF MONOLAYER CULTURE ON PAR-2 mRNA
EXPRESSION IN CHONDROCYTES
Chondrocytes dedifferentiate during long-term in vitro cul-
ture, and accordingly show considerable alteration of the
expression patterns of matrix components and cell surface
markers28,29. Therefore, it is important to understand how
in vitro culture will affect phenotypic change, by comparing
the cells’ potential to produce collagens, proteoglycans or
other components in the culture system used in each study.
To assess the inﬂuence of the dedifferentiation of mono-
layer-cultured chondrocytes on PAR-2 expression, we cul-
tured both normal and OA chondrocytes until passage 6
and analyzed the expression of PAR-2 and the collagen
type II gene, COL2A1.
As shown in Fig. 4, COL2A1 mRNA quickly decreased
from passage 2 in normal chondrocytes and from passage
1 in OA chondrocytes. In contrast with collagen type II,
PAR-2 mRNA decreased from passage 4 in OA chondro-
cytes, and was maintained at a very low level in normal
chondrocytes from fresh cells up to passage 6 (Fig. 4).
These results demonstrate that the expression of PAR-2
mRNA is maintained relatively unchanged over a longer pe-
riod than type II collagen in monolayer cultured
chondrocytes.
IL-1b UPREGULATES PAR-2 mRNA IN A CONCENTRATION-
DEPENDENT MANNER IN NORMAL AND OA CHONDROCYTES
To investigate the inﬂuence of IL-1b on expression of
PAR-2 in chondrocytes, we stimulated cultured chondro-
cytes at passage 1 with different doses of IL-1b for different
durations (Fig. 5). To observe PAR-2 mRNA expression in
response to different concentration of IL-1b, we stimulated
chondrocytes with different amounts of IL-1b for 24 h. IL-1b
increased mRNA levels of PAR-2 ﬁve-fold in normal chon-
drocytes and three-fold in OA chondrocytes in a concentra-
tion-dependent manner (P< 0.05 at 10 ng/ml or above)
[Fig. 5(b)]. Comparison of the arbitrary units of PAR-2
mRNA between normal and OA chondrocytes after stimula-
tion by IL-1b, showed that the upregulation by IL-1b in OA
chondrocytes was much greater than in normal ones
(P< 0.05 at 10 ng/ml or above) [Fig. 5(a)]. For time-course
analysis, the chondrocytes were stimulated with 10 ng/ml
of IL-1b for 12, 24, and 48 h. OA chondrocytes responded
more sensitively than normal ones to IL-1b at earlier times af-
ter stimulation when comparing either arbitrary units or fold
increases. The PAR-2 mRNA increase reached 10.5-fold in
OA chondrocytes whereas normal cells responded with
only a ﬁve-fold increase when stimulated by IL-1b for 12 h
(P< 0.05 for both) [Fig. 5(c and d)]. IL-1b upregulated
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each real-time PCR product, standard curves were generated by measuring the ﬂuorescence vs cycle number over a dilution range of the
constructs. PAR-2 standard curve (a representative result) is shown. Left, ﬂuorescence vs cycles for different dilutions of copy number of
the PAR-2 construct. Right, the standard curve for determining the arbitrary units of PAR-2. (b) Real-time PCR was performed to evaluate
the PAR-2 mRNA level expressed in chondrocytes from three samples of normal (NC) and eight samples of OA (OC) cartilage tissues, as
well as in synovial ﬁbroblast-like cells from normal (NFLS) and OA (OFLS) synovial tissues of the same patient. mRNA levels in the cells
were normalized to the mRNA level of b-actin and are expressed as the arbitrary units of PAR-2 mRNA per 1000 mRNA copies of b-actin
expressed in the same cells.PAR-2 expression in OA chondrocytes for the entire duration
of stimulation, although the effects decreased after 24 h. In
contrast with OA chondrocytes, normal chondrocytes tended
to decrease PAR-2 expression levels after longer than 24 h
stimulation by IL-1b. These results demonstrate differences
in the upregulation of PAR-2 gene expression in normal
and OA chondrocytes by IL-1b.
To further evaluate the upregulatory effect of IL-1b on
PAR-2 expression in chondrocytes at protein level, we
stimulated chondrocytes with IL-1b for 24 h and detected
PAR-2 protein in whole cell lysates by WB. PAR-2 inIL-1b-stimulated cells was augmented 2.5 fold (P< 0.05)
[Fig. 3(b)]. Thus, we have demonstrated upregulation of
PAR-2 in chondrocytes by IL-1b at both mRNA and pro-
tein levels.
TNF-a UPREGULATES PAR-2 mRNA IN A TIME-DEPENDENT
MANNER IN OA CHONDROCYTES
The inﬂuence of TNF-a on expression of PAR-2 mRNA in
cultured chondrocytes was observed (Fig. 6). Chondrocytes
at passage 1 were stimulated with different amounts ofFig. 3. Comparison of PAR-2 protein levels between normal and OA chondrocytes and FLS by WB. (a) WB was performed to evaluate PAR-2
protein levels in three normal and eight OA samples of cultured chondrocytes at passage 1 as well as in three NFLS and eight OFLS samples
from the same patients. Mouse anti-PAR-2 antibody was diluted to 1:200 in PBS containing 0.05% Tween 20 as the primary antibody, while
the secondary antibody was horse radish peroxidase-conjugated sheep anti-mouse IgG diluted to 1:10,000. WB results of three normal sam-
ples (NC-1 to -3), three OA samples (OC-1 to -3) as well as one NFLS and one OFLS sample are shown as representatives; upper panel, WB
of PAR-2 protein and GAPDH; lower panel, the relative levels of PAR-2 protein extrapolated from the band intensity ratio of PAR-2/GAPDH.
Asterisk (*) indicates a signiﬁcant difference in PAR-2 protein levels between normal and OA cells and between chondrocytes and FLS.
*P< 0.05; ***P< 0.001. (b) WB was performed with cytokine-stimulated cell lysates to quantify the effect of stimulation by IL-1b, TNF-a and
TGF-b for 24 h on protein levels. Upper panel, the representative WB results from one healthy (NC) and one OA chondrocyte (OC)
sample in the absence (non) or presence of stimulants (IL-1b, TNF-a and TGF-b); lower panel, the relative levels of PAR-2 protein
estimated from the band intensity ratio of PAR-2/GAPDH.
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a signiﬁcantly upregulated the expression of PAR-2 and the
highest level (4.9-fold increase) was induced by the lowest
concentration (1 ng/ml) (P< 0.05 for all concentrations). In
normal chondrocytes, TNF-a also increased the level of
PAR-2, however, a large variation in responses to TNF-a be-
tween different samples of normal chondrocytes was
Fig. 4. Expression of PAR-2 in chondrocytes at different passages.
Real-time PCR was performed to evaluate the PAR-2 mRNA level
expressed in chondrocytes at different passages from three sam-
ples of normal (NC) and three samples of OA chondrocytes (OC).
Total RNA was extracted from uncultured fresh chondrocytes
(fresh), and from cultured chondrocytes at passages from 0 to 6
(P0 to P6). The differences between mean PAR-2 mRNA levels
were compared between OA and normal chondrocytes.
*P< 0.05; ***P< 0.001.observed. The difference between stimulated (by 10 and
100 ng/ml) and unstimulated cells did not reach statistical
signiﬁcance (P> 0.05).
For the time course, we stimulated chondrocytes with
10 ng/ml of TNF-a for varying durations, as shown in
Fig. 6(c and d). In OA chondrocytes, PAR-2 mRNA in-
creased at 12 h and reached the highest level (6.6-fold) at
48 h which was statistically signiﬁcant (P< 0.05) when
comparing either arbitrary units or fold increase [Fig. 6(c
and d)]. In normal chondrocytes, PAR-2 mRNA also in-
creased at 12 and 24 h, however, no statistically signiﬁcant
differences were established (P> 0.05). Interestingly, TNF-
a also decreased PAR-2 levels in normal chondrocytes at
48 h, in the same way as IL-1b did in normal chondrocytes.
To test the regulatory effect of TNF-a on PAR-2 expres-
sion at the protein level, we also performed WB with lysates
of TNF-a-stimulated chondrocytes [Fig. 3(b)]. The results
showed that TNF-a increased production of PAR-2 protein
more than two-fold in both OA and normal chondrocytes
which corresponded with the stimulatory effect on PAR-2
mRNA.
TGF-b1 REGULATES PAR-2 IN OPPOSITE DIRECTIONS
IN NORMAL AND OA CHONDROCYTES
TGF-b is considered as an anabolic factor in articular
cartilage, where it regulates synthesis of ECM proteins
and plays a crucial role in cartilage repair and the patho-
genesis of OA. To evaluate the inﬂuence of TGF-b on
expression of PAR-2 in chondrocytes, recombinant humanFig. 5. Regulation of PAR-2 expression in chondrocytes by IL-1b. (a and b) Concentration-response. Total RNA was extracted from eight sam-
ples of OA chondrocytes and three samples of normal chondrocytes after culture in FCS-free DMEM without or with 1, 10 or 100 ng/ml IL-1b
for 24 h. Results were normalized to the b-actin mRNA level and the normalized PAR-2 expression in IL-1b-stimulated and unstimulated chon-
drocytes was compared. The changes of PAR-2 mRNA in arbitrary units (a) and the fold-change in PAR-2 mRNA (b) in chondrocytes without
and with stimulation by different concentration of IL-1b are shown. (c and d) Time course. Total RNA was extracted from chondrocytes after
culture in FCS-free DMEM without or with 10 ng/ml IL-1b for 12, 24 and 48 h. The changes in PAR-2 mRNA in arbitrary units (c) and the fold
change in PAR-2 (d) before and after stimulation by IL-1b for different durations are shown. NC, normal chondrocytes; OC, OA chondrocytes;
Non, unstimulated chondrocytes. *P< 0.05; **P< 0.01.
1169Osteoarthritis and Cartilage Vol. 14, No. 11Fig. 6. Regulation of PAR-2 expression in chondrocytes by TNF-a. (a and b) Concentration-response. Total RNA was extracted from eight
samples of OA chondrocytes (OC) and three samples of normal chondrocytes (NC) after culture in FCS-free DMEM without or with 1, 10
or 100 ng/ml TNF-a for 24 h. The b-actin-normalized mRNA expression levels of PAR-2 in TNF-a-stimulated and unstimulated chondrocytes
were compared. The changes in PAR-2 mRNA arbitrary units (a) and the fold increase of PAR-2 (b) in chondrocytes without and with stim-
ulation by different concentrations of TNF-a are shown.(c and d) Time course. Total RNA was extracted from chondrocytes after culture in
FCS-free DMEM without or with 10 ng/ml TNF-a for 12, 24 and 48 h. The changes in PAR-2 mRNA arbitrary unit (c) and the fold-change
in PAR-2 (d) before and after stimulation by TNF-a for different durations are shown. NC, normal chondrocytes; OC, OA chondrocytes;
Non, unstimulated chondrocytes. *P< 0.05; **P< 0.01.TGF-b1 was used to stimulate cultured chondrocytes at
passage 1 (Fig. 7). To investigate PAR-2 mRNA expres-
sion in response to different amounts of TGF-b1, cultured
chondrocytes were stimulated with 0.1, 1, or 10 ng/ml
TGF-b1 for 24 h. In contrast with IL-1b and TNF-a,
TGF-b1 signiﬁcantly down-regulated PAR-2 expression
in OA chondrocytes at concentrations of 1.0 and 10 ng/
ml (P< 0.05, for both) [Fig. 7(a and b)]. To our surprise,
however, TGF-b1 upregulated PAR-2 in normal chondro-
cytes at concentrations from 0.1 to 10 ng/ml and reached
a 6.7-fold increase at 1.0 ng/ml (P< 0.05 for concentra-
tions of 1.0 and 10.0 ng/ml).
For the time course, chondrocytes were stimulated with
1 ng/ml of TGF-b1 for 12, 24, and 48 h. In OA chondrocytes
TGF-b1 down-regulated PAR-2 expression in a time-
dependent manner, and the differences at 24 and 48 h
reached statistical signiﬁcance (P< 0.05). TGF-b1 was
also found to upregulate PAR-2 in normal chondrocytes at
12 and 24 h, but down-regulated PAR-2 at 48 h [Fig. 7(c
and d)]. These results demonstrate that TGF-b1 plays
different roles in the regulation of PAR-2 expression in nor-
mal and OA chondrocytes. More interestingly, the levels
reached (in arbitrary units) after upregulation of PAR-2
mRNA in normal chondrocytes were almost the same as
the levels reached after down-regulation of PAR-2 in OA
chondrocytes.
The opposite regulation of PAR-2 expression in OA and
normal chondrocytes by TGF-b1 was also observed at the
protein level by WB [Fig. 3(b)]. TGF-b1 signiﬁcantly
decreased production of PAR-2 in OA chondrocytes(P< 0.05). TGF-b1 increased PAR-2 protein in normal
chondrocytes as it did at mRNA level, however, the
changes before and after stimulation did not meet statistical
signiﬁcance (P> 0.05).
IL-1b AND TNF-a INCREASE THE AMOUNT OF PAR-2 IN
CULTURED CHONDROCYTES BOTH IN THE CYTOPLASM
AND THE CELL MEMBRANE
To further conﬁrm the regulation of PAR-2 expression by
IL-1b, TNF-a and TGF-b in chondrocytes, we cultured nor-
mal and OA chondrocytes in chamber-slides and stimulated
them with IL-1b, TNF-a and TGF-b, then investigated the
change in PAR-2 protein by IFA. Comparing the pattern of
distribution of PAR-2 between cells with and without stimu-
lation by IL-1b and TNF-a, we found that PAR-2 was mainly
localized in the cytoplasm at low levels before stimulation,
while after stimulation the density of PAR-2 in the mem-
brane was markedly enhanced [Fig. 8(III, IV, IX and X)], ac-
companied by an increase in the total amount of PAR-2
which was further veriﬁed by WB [Fig. 3(b)]. In addition,
the suppression of PAR-2 in OA chondrocytes by TGF-b is
also conﬁrmed by IFA [Fig.8(V and XI)].
Discussion
Accumulating evidence has demonstrated that inﬂamma-
tion is involved in the pathogenesis of OA at both synovio-
cyte and chondrocyte levels30,31. As a cell type unique to
1170 Y. Xiang et al.: Expression of PAR-2 in articular chondrocytesFig. 7. Regulation of PAR-2 expression in chondrocytes by TGF-b1. (a and b) Concentration-response. Total RNA was extracted from eight
samples of OA chondrocytes and three samples of normal chondrocytes after culture in FCS-free DMEM without or with 0.1, 1 or 10 ng/ml
TGF-b1 for 24 h. The b-actin-normalized mRNA expression levels of PAR-2 in TGF-b1-stimulated and unstimulated chondrocytes were com-
pared. The changes in PAR-2 mRNA arbitrary units (a) and the fold change in PAR-2 (b) before and after stimulation by different concentra-
tions of TGF-b1 are shown. (c and d) Time course. Total RNA was extracted from chondrocytes after culture in FCS-free DMEM without or with
1.0 ng/ml TGF-b1 for 12, 24 and 48 h. The changes in PAR-2 mRNA arbitrary units (c) and the fold change in PAR-2 (d) after stimulation with
TGF-b1 for different durations are shown. NC, normal chondrocytes; OC, OA chondrocytes; Non, unstimulated chondrocytes. *P< 0.05;
**P< 0.01.
Fig. 8. Comparison of PAR-2 synthesis by IFA in cultured chondrocytes before and after stimulation. Chondrocytes from three normal and
three OA samples, cultured in eight-well chamber-slides and incubated in the absence or presence of IL-1b (10 ng/ml), TNF-a (10 ng/ml)
and TGF-b1 (1 ng/ml) for 24 h, were stained with mouse anti-human PAR-2 IgG (SAM11) and then visualized with FITC-labeled rabbit
anti-mouse IgG. Upper panel (IeVI), OA chondrocytes; lower panel (VIIeXII), normal chondrocytes. I and VII, hematoxylin-stained unstimu-
lated chondrocytes matching II and VIII, the representative phase contrast; II and VIII, unstimulated chondrocytes; III and IX, cells stimulated
with IL-1b; IV and X, cells stimulated with TNF-a; V and XI, cells stimulated with TGF-b; VI and XII, mouse IgG was used in place of anti-PAR-2
antibody as negative controls.
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OA by releasing cytokines and enzymes into the surround-
ing matrix. For this reason, investigation of the expression
of PAR-2 and its modulation in chondrocytes is a logical ﬁrst
step in studying the consequences of PAR-2 activation in
chondrocytes and its potential in OA pathogenesis. In the
present study, we investigated baseline PAR-2 expression
in human articular chondrocytes and demonstrated the en-
hanced level of PAR-2 expression in OA chondrocytes
compared to normal cells.
We observed that freshly isolated, uncultured chondro-
cytes, as well as chondrocytes in primary culture, expressed
PAR-2 mRNA. By RT-PCR analysis, PAR-2 mRNA was
found to be the only one among four members of the PAR
family expressed in human chondrocytes. The expression
proﬁle of the PARs may distinguish chondrocytes from FLS,
since the ﬁbroblasts expressedPAR-1 andPAR-3 in addition
to PAR-2. Real-time PCR analysis showed enhanced ex-
pression ofPAR-2mRNA inOAsamples compared to normal
samples, both in synovial ﬁbroblastic cells and in chondro-
cytes. The difference in expression level of the proteins
between chondrocytes and FLS and between normal and
OA cells was conﬁrmed by Western blotting (WB).
The effect of in vitro culture of chondrocytes on PAR-2
expression was also explored. Chondrocytes in monolayer
culture are known to dedifferentiate and acquire a ﬁbroblas-
tic phenotype accompanied by increased production of col-
lagen type I and decreased production of collagen type II
and aggrecan32. Fibroblasts from a variety of tissues are
known to express PAR-2, and we have also demonstrated
in the present study that PAR-2 is expressed in synovial ﬁ-
broblastic cells at a much higher level than in chondrocytes.
However, our study on chondrocytes at a range of stages
from uncultured fresh cells to cells at passage 6, demon-
strated that dedifferentiation of chondrocytes decreases
the PAR-2 mRNA level from passage 4 onwards. This result
suggests that regulation of PAR-2 expression differs be-
tween ﬁbroblasts and dedifferentiated ﬁbroblast-like
chondrocytes.
In the present study, OA chondrocytes were found to ex-
press PAR-2 at a level seven times higher than normal
cells. This could be due to the effects of soluble factors
present in the synovial ﬂuid of OA patients, including IL-1
or TNF-a produced by synoviocytes and/or chondrocytes
in the joints in response to inﬂammatory stimuli33. To test
this hypothesis, we stimulated cultured chondrocytes at
passage 1 with IL-1b and TNF-a, the two most important
catabolic cytokines, as well as TGF-b, the well-known ana-
bolic cytokine produced by chondrocytes in cartilage. Con-
sistent with previous reports in human endothelial cells34,
both IL-1b and TNF-a upregulate PAR-2 mRNA expression
in chondrocytes. However, the response of chondrocytes to
IL-1b is different from that induced by TNF-a. IL-1b upregu-
lates PAR-2 mRNA expression both in normal and OA
chondrocytes soon after stimulation in a concentration-
dependent manner, resulting in a three-fold increase in
PAR-2 expression in OA chondrocytes and ﬁve-fold in nor-
mal cells at 24 h. However, in comparison with PAR-2
mRNA levels expressed by normal chondrocytes, the sen-
sitivity of OA chondrocytes in response to IL-1b is greater
than that of normal chondrocytes at an early stage of stim-
ulation; the average PAR-2 mRNA level, in arbitrary units, in
OA chondrocytes was enhanced from 21 to 233 at 12 h,
while the PAR-2 mRNA expression level in normal chondro-
cytes remained at a low level after stimulation. The high
sensitivity of PAR-2 to modulation by IL-1b in OA chondro-
cytes could be due to the primary chondrocyte activation inOA cartilage lesions by a variety of factors including proin-
ﬂammatory cytokines. In contrast to IL-1b, TNF-amainly up-
regulates PAR-2 mRNA in OA chondrocytes at low
concentrations in a time-dependent manner, which implies
a distinct regulatory effect of TNF-a on PAR-2 in OA. The
upregulatory effect of IL-1b and TNF-a on PAR-2 was fur-
ther conﬁrmed at the protein level by WB and IFA. IL-1b
and TNF-a both induced chondrocytes to produce PAR-2
and enhanced the amount of PAR-2 in the membrane,
both of which would amplify the biological function of
PAR-2. Thus, IL-1b and TNF-a, produced and secreted by
chondrocytes in OA cartilage35, may stimulate chondro-
cytes to express PAR-2 via autocrine and paracrine mech-
anisms. As reported in airway epithelial cells36 and prostate
cancercell lines37, activatedPAR-2mightstimulateproduction
of proteinases, such as MMPs and trypsin-like proteinases, in
chondrocytes leading to the degradation of cartilage. Activa-
tion of PAR-2 by trypsin-like proteinases may also increase
production of IL-1b and TNF-a as well as other proinﬂamma-
tory factors. This vicious circle may accelerate destruction of
cartilage and contribute to the pathophysiology of OA.Consid-
eringchronicandgradual damageof cartilage in thepathogen-
esis of OA, the long-term upregulation of PAR-2 expression in
chondrocytes by TNF-amight play a more important role than
regulation by IL-1b. Nevertheless, it should be noted that the
response to the cytokines may vary considerably between in-
dividuals (asshown inFig. 6(b), suggesting theexistenceof re-
sponders and nonresponders to each factor.
As an anabolic cytokine in cartilage, TGF-b stimulates
cartilage ECM synthesis and induces tissue inhibitor of
metalloproteinases 3, an inhibitor of cartilage-damaging
matrix metalloproteinases and aggrecanases. Recently,
TGF-b has been demonstrated to upregulate PAR-2 ex-
pression in several ﬁbroblastic cell lines38. We therefore hy-
pothesized that TGF-bmay also regulate PAR-2 expression
in chondrocytes. Our present study showed an opposite-
directional regulatory function of TGF-b on expression of
PAR-2 in normal and OA chondrocytes in vitro at both
mRNA and protein levels. That is, TGF-b upregulates the
expression of PAR-2 in normal chondrocytes in which
PAR-2 is at a low level, but down-regulates PAR-2 in OA
chondrocytes in which PAR-2 is overexpressed. These re-
sults suggest that TGF-b exerts its anabolic effects partially
through regulation of PAR-2 expression both in normal and
OA chondrocytes. TGF-b thus has a normalizing effect,
increasing PAR-2 in normal chondrocytes to accelerate car-
tilage turnover, and suppressing the overexpression of
PAR-2 in OA chondrocytes to indirectly inhibit cartilage
degradation.
The precisemechanisms bywhichPAR-2 is involved in the
induction or perpetuation of inﬂammation remain to be under-
stood. One possible explanation is the induction of proinﬂam-
matory cytokines by PAR-2 signaling; activation of PAR-2 by
trypsin or other PAR-2 agonists in PAR-2-expressing cells
in vitro is reported to induce proinﬂammatory cytokines and
mediators including IL-1b, IL-5, IL-6, IL-8, IL-13, monocyte
chemoattractant protein 1, TNF, macrophage inﬂammatory
protein (MIP)-2, eosinophil survival-promoting factors (GM-
CSF)9,31e44, intercellular adhesionmolecule-145, prostaglandin-
E2 (PGE2 )
43, and nitric oxide46,47. PAR-2 has also been
demonstrated to have proliferation-stimulating effects on ﬁ-
broblasts48, vascular endothelial cells49, and smooth muscle
cells50,51. On the other hand, the expression of PAR-2 is
regulated by a variety of proinﬂammatory cytokines and
mediators, such as IL-1a and b, TNF-a, and lipopolysaccha-
ride34. Two growth factors, Platelet-derived growth factor
(PDGF)-BB and TGF-b also upregulate PAR-2 expression
1172 Y. Xiang et al.: Expression of PAR-2 in articular chondrocytesin several ﬁbroblast cell lines38. These ﬁndings imply that, in
a tissue in which such mediators are available, PAR-2-medi-
ated signaling may play a role in regulating inﬂammatory re-
actions since the expression of PAR-2 is relatively
ubiquitous.
In summary, the present study demonstrates the expres-
sion of PAR-2 in articular chondrocytes in vitro from patients
with and without OA. Both catabolic and anabolic cytokines,
IL-1b and TNF-a, as well as TGF-b1, participate in the reg-
ulation of expression of PAR-2 in chondrocytes. Consider-
ing the overexpression of PAR-2 in OA chondrocytes and
its upregulation by IL-1b and TNF-a, PAR-2 may play
a pathological role in OA. The suppression of PAR-2 ex-
pression in OA and its induction in normal chondrocytes
by TGF-b implicates PAR-2 in the turnover of cartilage.
The roles of PAR-2 in chondrocytes and in the pathogene-
sis of OA need to be further studied.
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